Form 4: Niagen Bioscience Director Acquires Significant Stock Options

Frank L. Jaksch Jr., a Director and 10% Owner of Niagen Bioscience, Inc., has acquired 20,000 stock options with an exercise price of $14.13, vesting fully by June 24, 2026.

Summary

• Frank L. Jaksch Jr., a Director and 10% Owner of Niagen Bioscience, Inc. (NAGE), reported the acquisition of 20,000 derivative securities in the form of stock options.
• The transaction date for the acquisition of these options was June 24, 2025.
• Each stock option grants the right to buy one share of common stock at an exercise price of $14.13.
• The options will vest 100% on June 24, 2026.
• The expiration date for these stock options is June 23, 2035.
• Following this reported transaction, Frank L. Jaksch Jr. beneficially owns 20,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director and significant owner is generally viewed as a positive signal, indicating insider confidence in the company's future prospects and potential for stock appreciation.

Positives

• The acquisition of stock options by a Director and 10% Owner, Frank L. Jaksch Jr., signals confidence in the future performance and growth potential of Niagen Bioscience, Inc.
• The vesting schedule aligns the director's long-term interests with shareholder value creation.

Future Outlook

The document does not provide forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on an insider's equity transaction.

Industry Context

The granting of stock options to directors and key executives is a standard practice in the biotechnology and broader corporate sectors. It serves as a common form of incentive compensation, aligning the interests of management with those of shareholders by providing a direct financial stake in the company's stock performance.

Comparison to Industry Standards

• The grant of stock options to directors is a widely accepted compensation practice across various industries, including biotechnology, aligning executive incentives with long-term shareholder value.
• The exercise price of $14.13 and the grant of 20,000 options are specific to Niagen Bioscience, Inc. and its compensation structure for Frank L. Jaksch Jr., and would typically be benchmarked against similar roles and company sizes within the biotech industry to assess competitiveness and fairness of compensation.

Stakeholder Impact

• Shareholders: May view the insider's acquisition of options as a positive signal of confidence in the company's future, potentially influencing investor sentiment.
• Management/Employees: The option grant aligns the director's financial interests with the company's long-term performance, potentially motivating efforts to increase shareholder value.

Next Steps

• The acquired stock options will vest 100% on June 24, 2026.

Key Dates

Keywords

Niagen Bioscience, NAGE, SEC Form 4, Insider Transaction, Stock Options, Director Compensation, Beneficial Ownership, Equity Grant